Literature DB >> 3683453

Trial of ganglioside therapy for diabetic neuropathy.

M Hallett1, T Flood, N Slater, J Dambrosia.   

Abstract

The efficacy of daily intramuscular injection of mixed gangliosides (Cronassial) for highly symptomatic diabetic neuropathy was investigated in a randomized double-blind trial. There were 37 patients treated with 40 mg of gangliosides or placebo for 12 weeks and studied with physical examination, symptom scales, and electrophysiologic parameters. There was no demonstrated benefit of therapy. Given the spontaneous variation in the measurements employed, larger numbers of patients would have been needed to identify a significant change of 10% owing to therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3683453     DOI: 10.1002/mus.880100907

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

1.  The Therapeutic Role of Gangliosides in Neurological Disorders.

Authors:  J S Schneider
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

2.  Immunohistological analyses of neutral glycosphingolipids and gangliosides in normal mouse skeletal muscle and in mice with neuromuscular diseases.

Authors:  M Cacic; K Sostarić; S Weber-Schürholz; J Müthing
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

Review 3.  Gangliosides. Their role in clinical neurology.

Authors:  E Nobile-Orazio; M Carpo; G Scarlato
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

4.  GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular Route.

Authors:  Erika Di Biase; Giulia Lunghi; Margherita Maggioni; Maria Fazzari; Diego Yuri Pomè; Nicoletta Loberto; Maria Grazia Ciampa; Pamela Fato; Laura Mauri; Emmanuel Sevin; Fabien Gosselet; Sandro Sonnino; Elena Chiricozzi
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

Review 5.  GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.

Authors:  Elena Chiricozzi; Giulia Lunghi; Erika Di Biase; Maria Fazzari; Sandro Sonnino; Laura Mauri
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 6.  Complex carbohydrates in drug development.

Authors:  R L Schnaar
Journal:  Adv Pharmacol       Date:  1992

Review 7.  Novel insights on GM1 and Parkinson's disease: A critical review.

Authors:  Maria Fazzari; Erika Di Biase; Giulia Lunghi; Laura Mauri; Elena Chiricozzi; Sandro Sonnino
Journal:  Glycoconj J       Date:  2022-01-22       Impact factor: 2.916

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.